ATE414537T1 - Antikörper enthaltende stabilisierte zubereitungen - Google Patents

Antikörper enthaltende stabilisierte zubereitungen

Info

Publication number
ATE414537T1
ATE414537T1 AT02762901T AT02762901T ATE414537T1 AT E414537 T1 ATE414537 T1 AT E414537T1 AT 02762901 T AT02762901 T AT 02762901T AT 02762901 T AT02762901 T AT 02762901T AT E414537 T1 ATE414537 T1 AT E414537T1
Authority
AT
Austria
Prior art keywords
preparations containing
containing antibodies
stabilized preparations
stabilized
acetyltryptophan
Prior art date
Application number
AT02762901T
Other languages
English (en)
Inventor
Tadao Yamazaki
Hiroko Konishi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE414537T1 publication Critical patent/ATE414537T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT02762901T 2001-08-29 2002-08-29 Antikörper enthaltende stabilisierte zubereitungen ATE414537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001258988 2001-08-29

Publications (1)

Publication Number Publication Date
ATE414537T1 true ATE414537T1 (de) 2008-12-15

Family

ID=19086420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02762901T ATE414537T1 (de) 2001-08-29 2002-08-29 Antikörper enthaltende stabilisierte zubereitungen

Country Status (6)

Country Link
US (1) US7682608B2 (de)
EP (1) EP1428537B1 (de)
JP (1) JP4342941B2 (de)
AT (1) ATE414537T1 (de)
DE (1) DE60229961D1 (de)
WO (1) WO2003018056A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
JP4253688B2 (ja) * 2006-11-30 2009-04-15 三洋化成工業株式会社 凍結乾燥用保護剤及び生理活性物質の製造方法
EP2114451A2 (de) * 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13-antikörperformulierungen und deren verwendung
KR20100029764A (ko) * 2007-05-16 2010-03-17 케이티비 투머포슝스케쉘샤프트 엠비에이치 저점성 안트라사이클린 제제
JP4812807B2 (ja) * 2007-06-27 2011-11-09 三洋化成工業株式会社 タンパク質含有水溶液安定化剤及びタンパク質含有水溶液の安定化方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20110086163A1 (en) * 2009-10-13 2011-04-14 Walbar Inc. Method for producing a crack-free abradable coating with enhanced adhesion
AU2011325974B2 (en) 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
MY199135A (en) * 2013-03-13 2023-10-17 Genentech Inc Formulations with reduced oxidation
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
CN104977408B (zh) * 2015-06-15 2016-09-14 暨南大学 一种筛选分泌特异性单克隆抗体杂交瘤细胞的方法与应用
EP3397243A1 (de) * 2015-12-30 2018-11-07 H. Hoffnabb-La Roche Ag Verwendung von tryptophanderivaten für proteinformulierungen
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157113A (en) 1987-08-10 1992-10-20 Miles Inc. Removal of nucleic acids from monoclonal antibody preparations
ATE82136T1 (de) 1987-08-10 1992-11-15 Miles Inc Gereinigtes igm.
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
JPH0768137B2 (ja) 1989-06-15 1995-07-26 株式会社ミドリ十字 アルブミン製剤及びその製法
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AUPO871997A0 (en) 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
AU752730B2 (en) * 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time

Also Published As

Publication number Publication date
EP1428537A4 (de) 2005-11-09
EP1428537B1 (de) 2008-11-19
JP4342941B2 (ja) 2009-10-14
JPWO2003018056A1 (ja) 2004-12-09
WO2003018056A1 (fr) 2003-03-06
US20040213785A1 (en) 2004-10-28
US7682608B2 (en) 2010-03-23
DE60229961D1 (de) 2009-01-02
EP1428537A1 (de) 2004-06-16

Similar Documents

Publication Publication Date Title
DE60229961D1 (de) Antikörper enthaltende stabilisierte zubereitungen
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
EP1674480A4 (de) Antikörper, der den die tgf-beta-aktivierung steuernden regionsabschnitt erkennt
EP1176195A4 (de) VERFAHREN ZUR KONTROLLE DER AKTIVITäT VON IMMUNOLOGISCH FUNKTIONELLEM MOLEKüL
WO2004041865A3 (en) Stabilized single domain antibodies
NO2017028I1 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
DE69638269D1 (de) Hochaffine humane antikörper gegen tumorantigene
DK1454138T3 (da) Immunocytokiner med moduleret selektivitet
EP1698640A4 (de) Verfahren zur stabilisierung von antikörpern und stabilisierte antikörperzubereitung vom lösungstyp
AU2003215188A1 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
CY1107652T1 (el) Μεθοδος ποσοτικης ανιχνευσης ζωντων επιθηλιακων κυτταρων ογκου σε ενα βιολογικο υγρο
BR9408167A (pt) Composto composição fungicida e método de controle de doenças em plantas
EE200300408A (et) Aktiivsete valkude saagise suurendamine
DK1025227T3 (da) Humane TOLL-homologer
ATE348852T1 (de) Ph-wert-geregeltes polyamidpulver
ITBO20010545A0 (it) Articolo per la coltivazione di specie orticole
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
DK0501215T3 (da) Fusionsproteiner indeholdende monoklonalt antistof, linker og beta-glucuronidase til pro-drug-aktivering, deres fremstillin
DE60012713D1 (de) Durch xanthurensäure modifizierte proteine
ATE250021T1 (de) Hydroxycyclopentanone
WO2003057821A3 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
EP1191037A4 (de) Mittel zur stabilisierung von hämoglobinen
BR0210575A (pt) Compostos de 2-(fenila 2,6-dissubstituìda)-4-aril-5-alquil-1,3-oxazolina úteis como inseticidas e acaricidas
DK1171470T3 (da) Antistoffer over for placentaprotein 13

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties